Abstract
Pityriasis rosea is an acute viral rash associated with reactivation of latent human herpersvirus types 6 and 7. The rash is characterized by the appearance of an initial lesion, called a herald patch, followed by additional smaller lesions of a similar appearance, primarily on the trunk. Pityriasis rosea lesions are oval, salmon-colored patches and plaques with central scale. The onset of the rash is sometimes preceded by symptoms of an upper respiratory tract infection. Pityriasis rosea is self-limiting, and does not require treatment unless patients require symptomatic relief. Oral antivirals initiated within the first week of symptoms are associated with speedier clearance of the rash. For most people there are no complications associated with the condition; however, women in their first 20 weeks of pregnancy who get pityriasis rosea experience higher rates of miscarriage, premature delivery, and perinatal problems.
This is a preview of subscription content, log in via an institution to check access.
References
Drago F, Broccolo F, Ciccarese G, Rebora A, Parodi A. Persistent pityriasis rosea: an unusual form of pityriasis rosea with persistent active HHV-6 and HHV-7 infection. Dermatology. 2015;230(1):23–6.
Broccolo F, Drago F, Careddu AM, Foglieni C, Turbino L, Cocuzza CE, Gelmetti C, Lusso P, Rebora AE, Malnati MS. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7. J Invest Dermatol. 2005;124(6):1234–40.
Blauvelt A. Chapter 42. Pityriasis rosea. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill; 2012. Available from: http://accessmedicine.mhmedical.com.ezproxy.cul.columbia.edu/content.aspx?bookid=392&Sectionid=41138739. Accessed 27 Feb 2015.
Drago F, Broccolo F, Zaccaria E, Malnati M, Cocuzza C, Lusso P, Rebora A. Pregnancy outcome in patients with pityriasis rosea. J Am Acad Dermatol. 2008;58(5 Suppl 1):S78–83.
Ganguly S. A randomized, double-blind, placebo-controlled study of efficacy of oral acyclovir in the treatment of pityriasis rosea. J Clin Diagn Res. 2014;8(5):YC01–4.
Drago F, Vecchio F, Rebora A. Use of high-dose acyclovir in pityriasis rosea. J Am Acad Dermatol. 2006;54(1):82–5.
Drago F, Ciccarese G, Rebora A, Parodi A. Relapsing pityriasis rosea. Dermatology. 2014;229(4):316–8.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Reich, D., Psomadakis, C.E., Buka, B. (2017). Pityriasis Rosea. In: Top 50 Dermatology Case Studies for Primary Care. Springer, Cham. https://doi.org/10.1007/978-3-319-18627-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-18627-6_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18626-9
Online ISBN: 978-3-319-18627-6
eBook Packages: MedicineMedicine (R0)